Assess whether the primary endpoint will survive FDA scrutiny (849f56)

SITUATION In a 505(b)(2) program relying on literature plus a bridging study, 505(b)(2) literature-to-product bridge table is the evidence after a CMO 483 that maps to the NDA CMC module. Labeling negotiator has to pick Proceed under protocol or Pause the pathway for this Pharma & Life Sciences CMC and Development Pathways close using 505(b)(2) literature-to-product bridge table.

DECISION Labeling negotiator in a 505(b)(2) program relying on literature plus a bridging study must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using 505(b)(2) literature-to-product bridge table after a CMO 483 that maps to the NDA CMC module.

HYPOTHESES TO TEST 1. 505(b)(2) literature-to-product bridge table reads as Proceed under protocol once a CMO 483 that maps to the NDA CMC module is lined up to the same Pharma & Life Sciences population. 2. 505(b)(2) literature-to-product bridge table is closer to Pause the pathway after a CMO 483 that maps to the NDA CMC module; Proceed under protocol would over-claim this CMC and Development Pathways extract. 3. Escalate safety review is still live in 505(b)(2) literature-to-product bridge table for labeling negotiator in a 505(b)(2) program relying on literature plus a bridging study. 4. 505(b)(2) literature-to-product bridge table is missing the fact labeling negotiator needs after a CMO 483 that maps to the NDA CMC module; stop this Pharma & Life Sciences close.

ANALYSIS REQUIRED 1. Test a protocol deviation versus a safety signal versus a filing gap on the primary endpoint will. 2. Check whether 505(b)(2) literature-to-product bridge table supports the labeled claim labeling negotiator would keep. 3. Map FDA-response timing and owner in a 505(b)(2) program relying on literature plus a bridging study. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read 505(b)(2) literature-to-product bridge table against a CMO 483 that maps to the NDA CMC module and write the one fact that would move the primary endpoint will for labeling negotiator.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (505(b)(2) literature-to-product bridge table after a CMO 483 that maps to the NDA CMC module). The follow-on CMC and Development Pathways action is what labeling negotiator does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on the primary endpoint will, then the evidence in 505(b)(2) literature-to-product bridge table, then the action for labeling negotiator - Hypothesis scorecard against 505(b)(2) literature-to-product bridge table: supported / rejected / untestable - Owner and next date for labeling negotiator in a 505(b)(2) program relying on literature plus a bridging study - What changes the primary endpoint will if a CMO 483 that maps to the NDA CMC module is later withdrawn